Ertugliflozin L-pyroglutamic acid

Ertugliflozin L-pyroglutamic acid

• CAS Number: 1210344-83-4
• UNSPSC Description: Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. Has the potential for the treatment of type 2 diabetes mellitus[2].
• Target Antigen: SGLT
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/Ertugliflozin_L-pyroglutamic_acid.html
• Solubility: DMSO : ≥ 125 mg/mL|H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: ClC1=CC=C([C@]23O[C@@](CO)(CO3)[C@@H](O)[C@H](O)[C@H]2O)C=C1CC4=CC=C(OCC)C=C4.O=C5CC[C@@H](C(O)=O)N5
• Molecular Weight: 566.00
• References & Citations: [1]Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60.|[2]Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56.|[3]Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):1609-19.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched